In this study, we established an RS signature containing six genes, including C15orf52, C1orf228, CEL, FUZ, PAK6, and SIRPG, which could predict the prognosis of BC patients well and more robust than traditional clinical indicators. This evidence concerns the gene FUZ and breast cancer.